Clinical Trials · NCT05110170

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Name: Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Gonadorelin

Phase: Phase 3
Recruitment status: Completed
Sponsor: Luye Pharma Group Ltd.
Enrollment: 188
Start date: Oct 2020
Locations: 1 site, China
Primary endpoint: Non-inferiority of LY01005 compared with ZOLADEX®: the percentage of subjects with serum E2 maintaining at postmenopausal level (≤30 pg/mL) from Week 4 to Week 12 after the first dose.

View Gonadorelin compound reference